Robert J. Motzer, Se Hoon Park, Raymond S. McDermott, Camillo Porta, Daniel Yick Chin Heng, Mauricio Burotto, Roberto Iacovelli, Elena Verzoni, Hernan Cutuli, John Haanen, Cristina Suarez, Guillermo de Velasco, Begoña P. Valderrama, Hans M. Westgeest, Sammy Yuan, Rodolfo F. Perini, Ding Wang, Manuela Schmidinger. "Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.lba417